Nick McDonald Published on 5/11/22 2:01 PM News
AGC Biologics is deeply concerned and grieved about the situation in Ukraine. We sincerely hope that peaceful life will return to everyone as soon as possible. We also stand in partnership with our parent company, AGC Inc., in providing support for the safety and wellbeing of our Ukrainian colleagues and their families.
Nick McDonald Published on 3/31/22 6:00 AM News
Press Release Published on 2/8/22 4:00 PM News, Company News, Partnership
Press Release Published on 1/18/22 1:15 PM News, Company News
Nick McDonald Published on 12/13/21 5:00 PM News
AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.
Nick McDonald Published on 12/7/21 10:39 AM News
AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.
Press Release Published on 12/1/21 6:03 AM News, Company News
AGC Biologics to produce Procizumab for early and late clinical Phases at the company’s Chiba and Copenhagen facilities
Press Release Published on 11/1/21 6:00 AM News
Nick McDonald Published on 9/13/21 5:00 PM News
Seattle – September 13, 2021 – AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
Matteo Pellegrino Published on 8/20/21 10:30 AM News
